Uncategorized
Kubota Vision Announces Submission of Novel VAP-1 Inhibitors to the NCI Developmental Therapeutics Program for Screening in Cancer Cell Lines
SEATTLE--(BUSINESS WIRE)--Kubota Vision Inc. (“Kubota Vision”), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the submission of novel Vascular Adhesion Protein-1 (VAP-1) inhibitor compounds discovered by Kubota Vision to the U.S. National Cancer Institute (NCI) Developmental Therapeutics Program (DTP) for screening in the NCI-60 Human Tumor Cell Lines Screen. The NCI DTP will evaluate the co